...
首页> 外文期刊>JCO Oncology Practice >Adoption of Telemedicine for Postoperative Follow-Up After Inpatient Cancer-Related Surgery
【24h】

Adoption of Telemedicine for Postoperative Follow-Up After Inpatient Cancer-Related Surgery

机译:Adoption of Telemedicine for Postoperative Follow-Up After Inpatient Cancer-Related Surgery

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE:The COVID-19 pandemic has resulted in significant changes in health care delivery, including the rapid adoption of telemedicine across multiple specialties and practice environments. This includes postoperative visits (POV), despite limited data on outcomes following these telemedicine POV. We sought to determine whether these types of visits successfully identify and address postoperative complications when compared with in-person POV.METHODS:This was a retrospective cohort study of patients undergoing elective inpatient cancer-related surgery from March 2020 through December 2020. The exposure variable was type of POV (telemedicine v in-person). The primary outcome was unplanned hospital readmission within 90 days, and secondary outcomes included 30-day readmission, length of stay of first readmission, and mortality.RESULTS:Five-hundred thirty-five patients underwent elective inpatient operations and met our inclusion criteria. Of these, 98 (18.5) had an initial telemedicine POV. There was no difference in 90-day readmission on the basis of POV type (16.3 telemedicine v 16.5 in-person, P = .99). Reasons for readmission did not differ between patients who underwent a telemedicine POV compared with in-person POV (all P > .05). After adjustment for patients' demographic and clinical factors, telemedicine POV was not associated with 90-day readmission (odds ratio, 0.89; 95 CI, 0.43 to 1.70; P = .77).CONCLUSION:Telemedicine POV use adopted during the COVID-19 pandemic did not increase risk of readmission when compared with in-person visits following inpatient oncologic surgery. These data can help inform policy on the continued use and application of telemedicine after the pandemic.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号